1.1 	A bill for an act
1.2 	relating to controlled substances; modifying Minnesota's schedules of controlled 
1.3 	substances;amending Minnesota Statutes 2022, section 152.02, subdivisions 2, 
1.4 	3, 5, 6.
1.5 	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

1.6 	Section 1. Minnesota Statutes 2022, section 152.02, subdivision 2, is amended to read:
1.7 		Subd. 2.Schedule I. (a) Schedule I consists of the substances listed in this subdivision.
1.8 	(b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the 
1.9 	following substances, including their analogs, isomers, esters, ethers, salts, and salts of 
1.10 	isomers, esters, and ethers, whenever the existence of the analogs, isomers, esters, ethers, 
1.11 	and salts is possible:
1.12 	(1) acetylmethadol;
1.13 	(2) allylprodine;
1.14 	(3) alphacetylmethadol (except levo-alphacetylmethadol, also known as levomethadyl 
1.15 	acetate);
1.16 	(4) alphameprodine;
1.17 	(5) alphamethadol;
1.18 	(6) alpha-methylfentanyl benzethidine;
1.19 	(7) betacetylmethadol;
1.20 	(8) betameprodine;
2.1 	(9) betamethadol;
2.2 	(10) betaprodine;
2.3 	(11) clonitazene;
2.4 	(12) dextromoramide;
2.5 	(13) diampromide;
2.6 	(14) diethyliambutene;
2.7 	(15) difenoxin;
2.8 	(16) dimenoxadol;
2.9 	(17) dimepheptanol;
2.10 	(18) dimethyliambutene;
2.11 	(19) dioxaphetyl butyrate;
2.12 	(20) dipipanone;
2.13 	(21) ethylmethylthiambutene;
2.14 	(22) etonitazene;
2.15 	(23) etoxeridine;
2.16 	(24) furethidine;
2.17 	(25) hydroxypethidine;
2.18 	(26) ketobemidone;
2.19 	(27) levomoramide;
2.20 	(28) levophenacylmorphan;
2.21 	(29) 3-methylfentanyl;
2.22 	(30) acetyl-alpha-methylfentanyl;
2.23 	(31) alpha-methylthiofentanyl;
2.24 	(32) benzylfentanyl beta-hydroxyfentanyl;
2.25 	(33) beta-hydroxy-3-methylfentanyl;
2.26 	(34) 3-methylthiofentanyl;
2.27 	(35) thenylfentanyl;
3.1 	(36) thiofentanyl;
3.2 	(37) para-fluorofentanyl;
3.3 	(38) morpheridine;
3.4 	(39) 1-methyl-4-phenyl-4-propionoxypiperidine;
3.5 	(40) noracymethadol;
3.6 	(41) norlevorphanol;
3.7 	(42) normethadone;
3.8 	(43) norpipanone;
3.9 	(44) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP);
3.10 	(45) phenadoxone;
3.11 	(46) phenampromide;
3.12 	(47) phenomorphan;
3.13 	(48) phenoperidine;
3.14 	(49) piritramide;
3.15 	(50) proheptazine;
3.16 	(51) properidine;
3.17 	(52) propiram;
3.18 	(53) racemoramide;
3.19 	(54) tilidine;
3.20 	(55) trimeperidine;
3.21 	(56) N-(1-Phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl);
3.22 	(57) 3,4-dichloro-N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N-
3.23 	methylbenzamide(U47700);
3.24 	(58) N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide(furanylfentanyl);
3.25 	(59) 4-(4-bromophenyl)-4-dimethylamino-1-phenethylcyclohexanol (bromadol);
3.26 	(60) N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide (Cyclopropryl 
3.27 	fentanyl);
3.28 	(61) N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide) (butyryl fentanyl);
4.1 	(62) 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine) (MT-45);
4.2 	(63) N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide (cyclopentyl 
4.3 	fentanyl);
4.4 	(64) N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide (isobutyryl fentanyl);
4.5 	(65) N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide (valeryl fentanyl);
4.6 	(66) N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide 
4.7 	(para-chloroisobutyryl fentanyl);
4.8 	(67) N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide (para-fluorobutyryl 
4.9 	fentanyl);
4.10 	(68) N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide 
4.11 	(para-methoxybutyryl fentanyl);
4.12 	(69) N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetamide (ocfentanil);
4.13 	(70) N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide (4-fluoroisobutyryl 
4.14 	fentanyl or para-fluoroisobutyryl fentanyl);
4.15 	(71) N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide (acryl fentanyl or 
4.16 	acryloylfentanyl);
4.17 	(72) 2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide (methoxyacetyl 
4.18 	fentanyl);
4.19 	(73) N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide (ortho-fluorofentanyl 
4.20 	or 2-fluorofentanyl);
4.21 	(74) N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide 
4.22 	(tetrahydrofuranyl fentanyl); and
4.23 	(75) Fentanyl-related substances, their isomers, esters, ethers, salts and salts of isomers, 
4.24 	esters and ethers, meaning any substance not otherwise listed under another federal 
4.25 	Administration Controlled Substance Code Number or not otherwise listed in this section, 
4.26 	and for which no exemption or approval is in effect under section 505 of the Federal Food, 
4.27 	Drug, and Cosmetic Act, United States Code , title 21, section 355, that is structurally related 
4.28 	to fentanyl by one or more of the following modifications:
4.29 	(i) replacement of the phenyl portion of the phenethyl group by any monocycle, whether 
4.30 	or not further substituted in or on the monocycle;
5.1 	(ii) substitution in or on the phenethyl group with alkyl, alkenyl, alkoxyl, hydroxyl, halo, 
5.2 	haloalkyl, amino, or nitro groups;
5.3 	(iii) substitution in or on the piperidine ring with alkyl, alkenyl, alkoxyl, ester, ether, 
5.4 	hydroxyl, halo, haloalkyl, amino, or nitro groups;
5.5 	(iv) replacement of the aniline ring with any aromatic monocycle whether or not further 
5.6 	substituted in or on the aromatic monocycle; or
5.7 	(v) replacement of the N-propionyl group by another acyl group.;
5.8 	(76) 1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,3- 
5.9 	dihydro-2H-benzo[d]imidazol-2-one (brorphine);
5.10 	(77) 4'-methyl acetyl fentanyl;
5.11 	(78) beta-hydroxythiofentanyl;
5.12 	(79) beta-methyl fentanyl;
5.13 	(80) beta'-phenyl fentanyl;
5.14 	(81) crotonyl fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2-enamide);
5.15 	(82) cyclopropyl fentanyl 
5.16 	(N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);
5.17 	(83) fentanyl carbamate;
5.18 	(84) isotonitazene (N,N-diethyl-2-(2-(4 
5.19 	isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine);
5.20 	(85) para-fluoro furanyl fentanyl;
5.21 	(86) para-methylfentanyl;
5.22 	(87) phenyl fentanyl;
5.23 	(88) ortho-fluoroacryl fentanyl;
5.24 	(89) ortho-fluorobutyryl fentanyl;
5.25 	(90) ortho-fluoroisobutyryl fentanyl;
5.26 	(91) ortho-methyl acetylfentanyl; and
5.27 	(92) thiofuranyl fentanyl.
6.1 	(c) Opium derivatives. Any of the following substances, their analogs, salts, isomers, 
6.2 	and salts of isomers, unless specifically excepted or unless listed in another schedule, 
6.3 	whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:
6.4 	(1) acetorphine;
6.5 	(2) acetyldihydrocodeine;
6.6 	(3) benzylmorphine;
6.7 	(4) codeine methylbromide;
6.8 	(5) codeine-n-oxide;
6.9 	(6) cyprenorphine;
6.10 	(7) desomorphine;
6.11 	(8) dihydromorphine;
6.12 	(9) drotebanol;
6.13 	(10) etorphine;
6.14 	(11) heroin;
6.15 	(12) hydromorphinol;
6.16 	(13) methyldesorphine;
6.17 	(14) methyldihydromorphine;
6.18 	(15) morphine methylbromide;
6.19 	(16) morphine methylsulfonate;
6.20 	(17) morphine-n-oxide;
6.21 	(18) myrophine;
6.22 	(19) nicocodeine;
6.23 	(20) nicomorphine;
6.24 	(21) normorphine;
6.25 	(22) pholcodine; and
6.26 	(23) thebacon.
6.27 	(d) Hallucinogens. Any material, compound, mixture or preparation which contains any 
6.28 	quantity of the following substances, their analogs, salts, isomers (whether optical, positional, 
7.1 	or geometric), and salts of isomers, unless specifically excepted or unless listed in another 
7.2 	schedule, whenever the existence of the analogs, salts, isomers, and salts of isomers is 
7.3 	possible:
7.4 	(1) methylenedioxy amphetamine;
7.5 	(2) methylenedioxymethamphetamine;
7.6 	(3) methylenedioxy-N-ethylamphetamine (MDEA);
7.7 	(4) n-hydroxy-methylenedioxyamphetamine;
7.8 	(5) 4-bromo-2,5-dimethoxyamphetamine (DOB);
7.9 	(6) 2,5-dimethoxyamphetamine (2,5-DMA);
7.10 	(7) 4-methoxyamphetamine;
7.11 	(8) 5-methoxy-3, 4-methylenedioxyamphetamine;
7.12 	(9) alpha-ethyltryptamine;
7.13 	(10) bufotenine;
7.14 	(11) diethyltryptamine;
7.15 	(12) dimethyltryptamine;
7.16 	(13) 3,4,5-trimethoxyamphetamine;
7.17 	(14) 4-methyl-2, 5-dimethoxyamphetamine (DOM);
7.18 	(15) ibogaine;
7.19 	(16) lysergic acid diethylamide (LSD);
7.20 	(17) mescaline;
7.21 	(18) parahexyl;
7.22 	(19) N-ethyl-3-piperidyl benzilate;
7.23 	(20) N-methyl-3-piperidyl benzilate;
7.24 	(21) psilocybin;
7.25 	(22) psilocyn;
7.26 	(23) tenocyclidine (TPCP or TCP);
7.27 	(24) N-ethyl-1-phenyl-cyclohexylamine (PCE);
7.28 	(25) 1-(1-phenylcyclohexyl) pyrrolidine (PCPy);
8.1 	(26) 1-[1-(2-thienyl)cyclohexyl]-pyrrolidine (TCPy);
8.2 	(27) 4-chloro-2,5-dimethoxyamphetamine (DOC);
8.3 	(28) 4-ethyl-2,5-dimethoxyamphetamine (DOET);
8.4 	(29) 4-iodo-2,5-dimethoxyamphetamine (DOI);
8.5 	(30) 4-bromo-2,5-dimethoxyphenethylamine (2C-B);
8.6 	(31) 4-chloro-2,5-dimethoxyphenethylamine (2C-C);
8.7 	(32) 4-methyl-2,5-dimethoxyphenethylamine (2C-D);
8.8 	(33) 4-ethyl-2,5-dimethoxyphenethylamine (2C-E);
8.9 	(34) 4-iodo-2,5-dimethoxyphenethylamine (2C-I);
8.10 	(35) 4-propyl-2,5-dimethoxyphenethylamine (2C-P);
8.11 	(36) 4-isopropylthio-2,5-dimethoxyphenethylamine (2C-T-4);
8.12 	(37) 4-propylthio-2,5-dimethoxyphenethylamine (2C-T-7);
8.13 	(38) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine 
8.14 	(2-CB-FLY);
8.15 	(39) bromo-benzodifuranyl-isopropylamine (Bromo-DragonFLY);
8.16 	(40) alpha-methyltryptamine (AMT);
8.17 	(41) N,N-diisopropyltryptamine (DiPT);
8.18 	(42) 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT);
8.19 	(43) 4-acetoxy-N,N-diethyltryptamine (4-AcO-DET);
8.20 	(44) 4-hydroxy-N-methyl-N-propyltryptamine (4-HO-MPT);
8.21 	(45) 4-hydroxy-N,N-dipropyltryptamine (4-HO-DPT);
8.22 	(46) 4-hydroxy-N,N-diallyltryptamine (4-HO-DALT);
8.23 	(47) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
8.24 	(48) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT);
8.25 	(49) 5-methoxy-α-methyltryptamine (5-MeO-AMT);
8.26 	(50) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
8.27 	(51) 5-methylthio-N,N-dimethyltryptamine (5-MeS-DMT);
9.1 	(52) 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT);
9.2 	(53) 5-methoxy-α-ethyltryptamine (5-MeO-AET);
9.3 	(54) 5-methoxy-N,N-dipropyltryptamine (5-MeO-DPT);
9.4 	(55) 5-methoxy-N,N-diethyltryptamine (5-MeO-DET);
9.5 	(56) 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT);
9.6 	(57) methoxetamine (MXE);
9.7 	(58) 5-iodo-2-aminoindane (5-IAI);
9.8 	(59) 5,6-methylenedioxy-2-aminoindane (MDAI);
9.9 	(60) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe);
9.10 	(61) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe);
9.11 	(62) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe);
9.12 	(63) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
9.13 	(64) 2-(4-Ethylthio-2,5-dimethoxyphenyl)ethanamine (2C-T-2);
9.14 	(65) N,N-Dipropyltryptamine (DPT);
9.15 	(66) 3-[1-(Piperidin-1-yl)cyclohexyl]phenol (3-HO-PCP);
9.16 	(67) N-ethyl-1-(3-methoxyphenyl)cyclohexanamine (3-MeO-PCE);
9.17 	(68) 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo);
9.18 	(69) 1-[1-(4-methoxyphenyl)cyclohexyl]-piperidine (methoxydine, 4-MeO-PCP);
9.19 	(70) 2-(2-Chlorophenyl)-2-(ethylamino)cyclohexan-1-one (N-Ethylnorketamine, 
9.20 	ethketamine, NENK);
9.21 	(71) methylenedioxy-N,N-dimethylamphetamine (MDDMA);
9.22 	(72) 3-(2-Ethyl(methyl)aminoethyl)-1H-indol-4-yl (4-AcO-MET); and
9.23 	(73) 2-Phenyl-2-(methylamino)cyclohexanone (deschloroketamine).
9.24 	(e) Peyote. All parts of the plant presently classified botanically as Lophophora williamsii 
9.25 	Lemaire, whether growing or not, the seeds thereof, any extract from any part of the plant, 
9.26 	and every compound, manufacture, salts, derivative, mixture, or preparation of the plant, 
9.27 	its seeds or extracts. The listing of peyote as a controlled substance in Schedule I does not 
9.28 	apply to the nondrug use of peyote in bona fide religious ceremonies of the American Indian 
9.29 	Church, and members of the American Indian Church are exempt from registration. Any 
10.1 	person who manufactures peyote for or distributes peyote to the American Indian Church, 
10.2 	however, is required to obtain federal registration annually and to comply with all other 
10.3 	requirements of law.
10.4 	(f) Central nervous system depressants. Unless specifically excepted or unless listed in 
10.5 	another schedule, any material compound, mixture, or preparation which contains any 
10.6 	quantity of the following substances, their analogs, salts, isomers, and salts of isomers 
10.7 	whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:
10.8 	(1) mecloqualone;
10.9 	(2) methaqualone;
10.10 	(3) gamma-hydroxybutyric acid (GHB), including its esters and ethers;
10.11 	(4) flunitrazepam;
10.12 	(5) 2-(2-Methoxyphenyl)-2-(methylamino)cyclohexanone (2-MeO-2-deschloroketamine, 
10.13 	methoxyketamine);
10.14 	(6) tianeptine;
10.15 	(7) clonazolam;
10.16 	(8) etizolam;
10.17 	(9) flubromazolam; and
10.18 	(10) flubromazepam.
10.19 	(g) Stimulants. Unless specifically excepted or unless listed in another schedule, any 
10.20 	material compound, mixture, or preparation which contains any quantity of the following 
10.21 	substances, their analogs, salts, isomers, and salts of isomers whenever the existence of the 
10.22 	analogs, salts, isomers, and salts of isomers is possible:
10.23 	(1) aminorex;
10.24 	(2) cathinone;
10.25 	(3) fenethylline;
10.26 	(4) methcathinone;
10.27 	(5) methylaminorex;
10.28 	(6) N,N-dimethylamphetamine;
10.29 	(7) N-benzylpiperazine (BZP);
11.1 	(8) methylmethcathinone (mephedrone);
11.2 	(9) 3,4-methylenedioxy-N-methylcathinone (methylone);
11.3 	(10) methoxymethcathinone (methedrone);
11.4 	(11) methylenedioxypyrovalerone (MDPV);
11.5 	(12) 3-fluoro-N-methylcathinone (3-FMC);
11.6 	(13) methylethcathinone (MEC);
11.7 	(14) 1-benzofuran-6-ylpropan-2-amine (6-APB);
11.8 	(15) dimethylmethcathinone (DMMC);
11.9 	(16) fluoroamphetamine;
11.10 	(17) fluoromethamphetamine;
11.11 	(18) α-methylaminobutyrophenone (MABP or buphedrone);
11.12 	(19) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone);
11.13 	(20) 2-(methylamino)-1-(4-methylphenyl)butan-1-one (4-MEMABP or BZ-6378);
11.14 	(21) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl) pentan-1-one (naphthylpyrovalerone or 
11.15 	naphyrone);
11.16 	(22) (alpha-pyrrolidinopentiophenone (alpha-PVP);
11.17 	(23) (RS)-1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-hexanone (4-Me-PHP or MPHP);
11.18 	(24) 2-(1-pyrrolidinyl)-hexanophenone (Alpha-PHP);
11.19 	(25) 4-methyl-N-ethylcathinone (4-MEC);
11.20 	(26) 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP);
11.21 	(27) 2-(methylamino)-1-phenylpentan-1-one (pentedrone);
11.22 	(28) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone);
11.23 	(29) 4-fluoro-N-methylcathinone (4-FMC);
11.24 	(30) 3,4-methylenedioxy-N-ethylcathinone (ethylone);
11.25 	(31) alpha-pyrrolidinobutiophenone (α-PBP);
11.26 	(32) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB);
11.27 	(33) 1-phenyl-2-(1-pyrrolidinyl)-1-heptanone (PV8);
12.1 	(34) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran (6-APDB);
12.2 	(35) 4-methyl-alpha-ethylaminopentiophenone (4-MEAPP);
12.3 	(36) 4'-chloro-alpha-pyrrolidinopropiophenone (4'-chloro-PPP);
12.4 	(37) 1-(1,3-Benzodioxol-5-yl)-2-(dimethylamino)butan-1-one (dibutylone, bk-DMBDB);
12.5 	(38) 1-(3-chlorophenyl) piperazine (meta-chlorophenylpiperazine or mCPP);
12.6 	(39) 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one (N-ethylpentylone, ephylone); 
12.7 	and
12.8 	(40) any other substance, except bupropion or compounds listed under a different 
12.9 	schedule, that is structurally derived from 2-aminopropan-1-one by substitution at the 
12.10 	1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the 
12.11 	compound is further modified in any of the following ways:
12.12 	(i) by substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, 
12.13 	haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring 
12.14 	system by one or more other univalent substituents;
12.15 	(ii) by substitution at the 3-position with an acyclic alkyl substituent;
12.16 	(iii) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or 
12.17 	methoxybenzyl groups; or
12.18 	(iv) by inclusion of the 2-amino nitrogen atom in a cyclic structure.;
12.19 	(41) 4,4'-dimethylaminorex (4,4'-DMAR; 
12.20 	4,5-dihydro-4-methyl-5-(4-methylphenyl)-2-oxazolamine);
12.21 	(42) 4-chloro-alpha-pyrrolidinovalerophenone (4-chloro-A-PVP);
12.22 	(43) para-methoxymethamphetamine (PMMA), 
12.23 	1-(4-methoxyphenyl)-N-methylpropan-2-amine; and
12.24 	(44) N-ethylhexedrone.
12.25 	(h) Marijuana, tetrahydrocannabinols, and synthetic cannabinoids. Unless specifically 
12.26 	excepted or unless listed in another schedule, any natural or synthetic material, compound, 
12.27 	mixture, or preparation that contains any quantity of the following substances, their analogs, 
12.28 	isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence 
12.29 	of the isomers, esters, ethers, or salts is possible:
12.30 	(1) marijuana;
13.1 	(2) tetrahydrocannabinols naturally contained in a plant of the genus Cannabis, except 
13.2 	that tetrahydrocannabinols do not include any material, compound, mixture, or preparation 
13.3 	that qualifies as industrial hemp as defined in section 18K.02, subdivision 3; synthetic 
13.4 	equivalents of the substances contained in the cannabis plant or in the resinous extractives 
13.5 	of the plant; or synthetic substances with similar chemical structure and pharmacological 
13.6 	activity to those substances contained in the plant or resinous extract, including, but not 
13.7 	limited to, 1 cis or trans tetrahydrocannabinol, 6 cis or trans tetrahydrocannabinol, and 3,4 
13.8 	cis or trans tetrahydrocannabinol;
13.9 	(3) synthetic cannabinoids, including the following substances:
13.10 	(i) Naphthoylindoles, which are any compounds containing a 3-(1-napthoyl)indole 
13.11 	structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, 
13.12 	alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 
13.13 	2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any 
13.14 	extent and whether or not substituted in the naphthyl ring to any extent. Examples of 
13.15 	naphthoylindoles include, but are not limited to:
13.16 	(A) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM-678);
13.17 	(B) 1-Butyl-3-(1-naphthoyl)indole (JWH-073);
13.18 	(C) 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081);
13.19 	(D) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);
13.20 	(E) 1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015);
13.21 	(F) 1-Hexyl-3-(1-naphthoyl)indole (JWH-019);
13.22 	(G) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);
13.23 	(H) 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210);
13.24 	(I) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);
13.25 	(J) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201).
13.26 	(ii) Napthylmethylindoles, which are any compounds containing a 
13.27 	1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the 
13.28 	indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 
13.29 	1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further 
13.30 	substituted in the indole ring to any extent and whether or not substituted in the naphthyl 
13.31 	ring to any extent. Examples of naphthylmethylindoles include, but are not limited to:
14.1 	(A) 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane (JWH-175);
14.2 	(B) 1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methane (JWH-184).
14.3 	(iii) Naphthoylpyrroles, which are any compounds containing a 3-(1-naphthoyl)pyrrole 
14.4 	structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, 
14.5 	alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 
14.6 	2-(4-morpholinyl)ethyl group whether or not further substituted in the pyrrole ring to any 
14.7 	extent, whether or not substituted in the naphthyl ring to any extent. Examples of 
14.8 	naphthoylpyrroles include, but are not limited to, 
14.9 	(5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone (JWH-307).
14.10 	(iv) Naphthylmethylindenes, which are any compounds containing a naphthylideneindene 
14.11 	structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, 
14.12 	cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 
14.13 	2-(4-morpholinyl)ethyl group whether or not further substituted in the indene ring to any 
14.14 	extent, whether or not substituted in the naphthyl ring to any extent. Examples of 
14.15 	naphthylemethylindenes include, but are not limited to, 
14.16 	E-1-[1-(1-naphthalenylmethylene)-1H-inden-3-yl]pentane (JWH-176).
14.17 	(v) Phenylacetylindoles, which are any compounds containing a 3-phenylacetylindole 
14.18 	structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, 
14.19 	alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 
14.20 	2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any 
14.21 	extent, whether or not substituted in the phenyl ring to any extent. Examples of 
14.22 	phenylacetylindoles include, but are not limited to:
14.23 	(A) 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8);
14.24 	(B) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);
14.25 	(C) 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251);
14.26 	(D) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).
14.27 	(vi) Cyclohexylphenols, which are compounds containing a 
14.28 	2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic 
14.29 	ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 
14.30 	1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not substituted 
14.31 	in the cyclohexyl ring to any extent. Examples of cyclohexylphenols include, but are not 
14.32 	limited to:
14.33 	(A) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497);
15.1 	(B) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol 
15.2 	(Cannabicyclohexanol or CP 47,497 C8 homologue);
15.3 	(C) 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl] 
15.4 	-phenol (CP 55,940).
15.5 	(vii) Benzoylindoles, which are any compounds containing a 3-(benzoyl)indole structure 
15.6 	with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, 
15.7 	cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 
15.8 	2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any 
15.9 	extent and whether or not substituted in the phenyl ring to any extent. Examples of 
15.10 	benzoylindoles include, but are not limited to:
15.11 	(A) 1-Pentyl-3-(4-methoxybenzoyl)indole (RCS-4);
15.12 	(B) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694);
15.13 	(C) (4-methoxyphenyl-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone (WIN 
15.14 	48,098 or Pravadoline).
15.15 	(viii) Others specifically named:
15.16 	(A) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl) 
15.17 	-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (HU-210);
15.18 	(B) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl) 
15.19 	-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (Dexanabinol or HU-211);
15.20 	(C) 2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de] 
15.21 	-1,4-benzoxazin-6-yl-1-naphthalenylmethanone (WIN 55,212-2);
15.22 	(D) (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144);
15.23 	(E) (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone 
15.24 	(XLR-11);
15.25 	(F) 1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3-carboxamide 
15.26 	(AKB-48(APINACA));
15.27 	(G) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide 
15.28 	(5-Fluoro-AKB-48);
15.29 	(H) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22);
15.30 	(I) 8-quinolinyl ester-1-(5-fluoropentyl)-1H-indole-3-carboxylic acid (5-Fluoro PB-22);
16.1 	(J) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole- 3-carboxamide 
16.2 	(AB-PINACA);
16.3 	(K) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]- 
16.4 	1H-indazole-3-carboxamide (AB-FUBINACA);
16.5 	(L) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H- 
16.6 	indazole-3-carboxamide(AB-CHMINACA);
16.7 	(M) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3- methylbutanoate 
16.8 	(5-fluoro-AMB);
16.9 	(N) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl) methanone (THJ-2201);
16.10 	(O) (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone) 
16.11 	(FUBIMINA);
16.12 	(P) (7-methoxy-1-(2-morpholinoethyl)-N-((1S,2S,4R)-1,3,3-trimethylbicyclo 
16.13 	[2.2.1]heptan-2-yl)-1H-indole-3-carboxamide (MN-25 or UR-12);
16.14 	(Q) (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl) 
16.15 	-1H-indole-3-carboxamide (5-fluoro-ABICA);
16.16 	(R) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl) 
16.17 	-1H-indole-3-carboxamide;
16.18 	(S) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl) 
16.19 	-1H-indazole-3-carboxamide;
16.20 	(T) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido) -3,3-dimethylbutanoate;
16.21 	(U) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1(cyclohexylmethyl)-1 
16.22 	H-indazole-3-carboxamide (MAB-CHMINACA);
16.23 	(V) N-(1-Amino-3,3-dimethyl-1-oxo-2-butanyl)-1-pentyl-1H-indazole-3-carboxamide 
16.24 	(ADB-PINACA);
16.25 	(W) methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate (FUB-AMB);
16.26 	(X) N-[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl]-1-(cyclohexylmethyl)-1H-Indazole-
16.27 	3-carboxamide. (APP-CHMINACA);
16.28 	(Y) quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FUB-PB-22); and
16.29 	(Z) methyl N-[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]valinate (MMB-CHMICA).
16.30 	(ix) Additional substances specifically named:
17.1 	(A) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1 
17.2 	H-pyrrolo[2,3-B]pyridine-3-carboxamide (5F-CUMYL-P7AICA);
17.3 	(B) 1-(4-cyanobutyl)-N-(2- phenylpropan-2-yl)-1 H-indazole-3-carboxamide 
17.4 	(4-CN-Cumyl-Butinaca);
17.5 	(C) naphthalen-1-yl-1-(5-fluoropentyl)-1-H-indole-3-carboxylate (NM2201; CBL2201);
17.6 	(D) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1 
17.7 	H-indazole-3-carboxamide (5F-ABPINACA);
17.8 	(E) methyl-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate 
17.9 	(MDMB CHMICA);
17.10 	(F) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate 
17.11 	(5F-ADB; 5F-MDMB-PINACA); and
17.12 	(G) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl) 
17.13 	1H-indazole-3-carboxamide (ADB-FUBINACA).;
17.14 	(H) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide;
17.15 	(I) (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3- tetramethylcyclopropyl)methanone;
17.16 	(J) methyl 2-(1-(4-fluorobenzyl)-1Hindazole-3-carboxamido)-3,3-dimethylbutanoate;
17.17 	(K) methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate;
17.18 	(L) ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate;
17.19 	(M) methyl 2-(1-(4-fluorobenzyl)-1Hindazole-3-carboxamido)-3- methylbutanoate;
17.20 	(N) N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide; and
17.21 	(O) N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide.
17.22 	(i) A controlled substance analog, to the extent that it is implicitly or explicitly intended 
17.23 	for human consumption.

17.24 	EFFECTIVE DATE. This section is effective the day following final enactment.

17.25 	Sec. 2. Minnesota Statutes 2022, section 152.02, subdivision 3, is amended to read:
17.26 		Subd. 3.Schedule II. (a) Schedule II consists of the substances listed in this subdivision.
17.27 	(b) Unless specifically excepted or unless listed in another schedule, any of the following 
17.28 	substances whether produced directly or indirectly by extraction from substances of vegetable 
18.1 	origin or independently by means of chemical synthesis, or by a combination of extraction 
18.2 	and chemical synthesis:
18.3 	(1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or 
18.4 	opiate.
18.5 	(i) Excluding:
18.6 	(A) apomorphine;
18.7 	(B) thebaine-derived butorphanol;
18.8 	(C) dextrophan;
18.9 	(D) nalbuphine;
18.10 	(E) nalmefene;
18.11 	(F) naloxegol;
18.12 	(G) naloxone;
18.13 	(H) naltrexone; and
18.14 	(I) their respective salts;
18.15 	(ii) but including the following:
18.16 	(A) opium, in all forms and extracts;
18.17 	(B) codeine;
18.18 	(C) dihydroetorphine;
18.19 	(D) ethylmorphine;
18.20 	(E) etorphine hydrochloride;
18.21 	(F) hydrocodone;
18.22 	(G) hydromorphone;
18.23 	(H) metopon;
18.24 	(I) morphine;
18.25 	(J) oxycodone;
18.26 	(K) oxymorphone;
18.27 	(L) thebaine;
18.28 	(M) oripavine;
19.1 	(2) any salt, compound, derivative, or preparation thereof which is chemically equivalent 
19.2 	or identical with any of the substances referred to in clause (1), except that these substances 
19.3 	shall not include the isoquinoline alkaloids of opium;
19.4 	(3) opium poppy and poppy straw;
19.5 	(4) coca leaves and any salt, cocaine compound, derivative, or preparation of coca leaves 
19.6 	(including cocaine and ecgonine and their salts, isomers, derivatives, and salts of isomers 
19.7 	and derivatives), and any salt, compound, derivative, or preparation thereof which is 
19.8 	chemically equivalent or identical with any of these substances, except that the substances 
19.9 	shall not include decocainized coca leaves or extraction of coca leaves, which extractions 
19.10 	do not contain cocaine or ecgonine;
19.11 	(5) concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid, 
19.12 	or powder form which contains the phenanthrene alkaloids of the opium poppy).
19.13 	(c) Any of the following opiates, including their isomers, esters, ethers, salts, and salts 
19.14 	of isomers, esters and ethers, unless specifically excepted, or unless listed in another schedule, 
19.15 	whenever the existence of such isomers, esters, ethers and salts is possible within the specific 
19.16 	chemical designation:
19.17 	(1) alfentanil;
19.18 	(2) alphaprodine;
19.19 	(3) anileridine;
19.20 	(4) bezitramide;
19.21 	(5) bulk dextropropoxyphene (nondosage forms);
19.22 	(6) carfentanil;
19.23 	(7) dihydrocodeine;
19.24 	(8) dihydromorphinone;
19.25 	(9) diphenoxylate;
19.26 	(10) fentanyl;
19.27 	(11) isomethadone;
19.28 	(12) levo-alpha-acetylmethadol (LAAM);
19.29 	(13) levomethorphan;
19.30 	(14) levorphanol;
20.1 	(15) metazocine;
20.2 	(16) methadone;
20.3 	(17) methadone - intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane;
20.4 	(18) moramide - intermediate, 2-methyl-3-morpholino-1, 1-diphenyl-propane-carboxylic 
20.5 	acid;
20.6 	(19) pethidine;
20.7 	(20) pethidine - intermediate - a, 4-cyano-1-methyl-4-phenylpiperidine;
20.8 	(21) pethidine - intermediate - b, ethyl-4-phenylpiperidine-4-carboxylate;
20.9 	(22) pethidine - intermediate - c, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
20.10 	(23) phenazocine;
20.11 	(24) piminodine;
20.12 	(25) racemethorphan;
20.13 	(26) racemorphan;
20.14 	(27) remifentanil;
20.15 	(28) sufentanil;
20.16 	(29) tapentadol;
20.17 	(30) 4-Anilino-N-phenethylpiperidine.;
20.18 	(31) oliceridine;
20.19 	(32) norfentanyl (N-phenyl-N-(piperidin-4-yl) propionamide).
20.20 	(d) Unless specifically excepted or unless listed in another schedule, any material, 
20.21 	compound, mixture, or preparation which contains any quantity of the following substances 
20.22 	having a stimulant effect on the central nervous system:
20.23 	(1) amphetamine, its salts, optical isomers, and salts of its optical isomers;
20.24 	(2) methamphetamine, its salts, isomers, and salts of its isomers;
20.25 	(3) phenmetrazine and its salts;
20.26 	(4) methylphenidate;
20.27 	(5) lisdexamfetamine.
21.1 	(e) Unless specifically excepted or unless listed in another schedule, any material, 
21.2 	compound, mixture, or preparation which contains any quantity of the following substances 
21.3 	having a depressant effect on the central nervous system, including its salts, isomers, and 
21.4 	salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible 
21.5 	within the specific chemical designation:
21.6 	(1) amobarbital;
21.7 	(2) glutethimide;
21.8 	(3) secobarbital;
21.9 	(4) pentobarbital;
21.10 	(5) phencyclidine;
21.11 	(6) phencyclidine immediate precursors:
21.12 	(i) 1-phenylcyclohexylamine;
21.13 	(ii) 1-piperidinocyclohexanecarbonitrile;
21.14 	(7) phenylacetone.
21.15 	(f) Cannabinoids:
21.16 	(1) nabilone;
21.17 	(2) dronabinol [(-)-delta-9-trans-tetrahydrocannabinol (delta-9-THC)] in an oral solution 
21.18 	in a drug product approved for marketing by the United States Food and Drug Administration.

21.19 	EFFECTIVE DATE. This section is effective the day following final enactment.

21.20 	Sec. 3. Minnesota Statutes 2022, section 152.02, subdivision 5, is amended to read:
21.21 		Subd. 5.Schedule IV. (a) Schedule IV consists of the substances listed in this subdivision.
21.22 	(b) Narcotic drugs. Unless specifically excepted or unless listed in another schedule, 
21.23 	any material, compound, mixture, or preparation containing any of the following narcotic 
21.24 	drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities 
21.25 	as follows:
21.26 	(1) not more than one milligram of difenoxin and not less than 25 micrograms of atropine 
21.27 	sulfate per dosage unit;
21.28 	(2) dextropropoxyphene (Darvon and Darvocet);
22.1 	(3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and 
22.2 	geometric isomers, and salts of these isomers (including tramadol);
22.3 	(4) eluxadoline;
22.4 	(5) pentazocine; and
22.5 	(6) butorphanol (including its optical isomers).
22.6 	(c) Depressants. Unless specifically excepted or unless listed in another schedule, any 
22.7 	material, compound, mixture, or preparation containing any quantity of the following 
22.8 	substances, including its salts, isomers, and salts of isomers whenever the existence of the 
22.9 	salts, isomers, and salts of isomers is possible:
22.10 	(1) alfaxalone (5α-pregnan-3α-ol-11,20-dione);
22.11 	(2) alprazolam;
22.12 	(3) barbital;
22.13 	(4) bromazepam;
22.14 	(5) camazepam;
22.15 	(6) carisoprodol;
22.16 	(7) chloral betaine;
22.17 	(8) chloral hydrate;
22.18 	(9) chlordiazepoxide;
22.19 	(10) clobazam;
22.20 	(11) clonazepam;
22.21 	(12) clorazepate;
22.22 	(13) clotiazepam;
22.23 	(14) cloxazolam;
22.24 	(15) delorazepam;
22.25 	(16) diazepam;
22.26 	(17) dichloralphenazone;
22.27 	(18) estazolam;
22.28 	(19) ethchlorvynol;
23.1 	(20) ethinamate;
23.2 	(21) ethyl loflazepate;
23.3 	(22) fludiazepam;
23.4 	(23) flurazepam;
23.5 	(24) fospropofol;
23.6 	(25) halazepam;
23.7 	(26) haloxazolam;
23.8 	(27) ketazolam;
23.9 	(28) loprazolam;
23.10 	(29) lorazepam;
23.11 	(30) lormetazepam mebutamate;
23.12 	(31) medazepam;
23.13 	(32) meprobamate;
23.14 	(33) methohexital;
23.15 	(34) methylphenobarbital;
23.16 	(35) midazolam;
23.17 	(36) nimetazepam;
23.18 	(37) nitrazepam;
23.19 	(38) nordiazepam;
23.20 	(39) oxazepam;
23.21 	(40) oxazolam;
23.22 	(41) paraldehyde;
23.23 	(42) petrichloral;
23.24 	(43) phenobarbital;
23.25 	(44) pinazepam;
23.26 	(45) prazepam;
23.27 	(46) quazepam;
24.1 	(47) suvorexant;
24.2 	(48) temazepam;
24.3 	(49) tetrazepam;
24.4 	(50) triazolam;
24.5 	(51) zaleplon;
24.6 	(52) zolpidem;
24.7 	(53) zopiclone.;
24.8 	(54) brexanolone (3α-hydroxy-5α-pregnan-20-one);
24.9 	(55) lemborexant;
24.10 	(56) remimazolam (4H-imidazol[1,2-a][1,4]benzodiazepine4-propionic acid).
24.11 	(d) Any material, compound, mixture, or preparation which contains any quantity of the 
24.12 	following substance including its salts, isomers, and salts of such isomers, whenever the 
24.13 	existence of such salts, isomers, and salts of isomers is possible: fenfluramine.
24.14 	(e) Stimulants. Unless specifically excepted or unless listed in another schedule, any 
24.15 	material, compound, mixture, or preparation which contains any quantity of the following 
24.16 	substances having a stimulant effect on the central nervous system, including its salts, 
24.17 	isomers, and salts of isomers:
24.18 	(1) cathine (norpseudoephedrine);
24.19 	(2) diethylpropion;
24.20 	(3) fencamfamine;
24.21 	(4) fenproporex;
24.22 	(5) mazindol;
24.23 	(6) mefenorex;
24.24 	(7) modafinil;
24.25 	(8) pemoline (including organometallic complexes and chelates thereof);
24.26 	(9) phentermine;
24.27 	(10) pipradol;
24.28 	(11) sibutramine;
25.1 	(12) SPA (1-dimethylamino-1,2-diphenylethane).;
25.2 	(13) serdexmethylphenidate;
25.3 	(14) solriamfetol (2-amino-3-phenylpropyl car-bamate; benzenepropanol, beta-amino-, 
25.4 	carbamate (ester)).
25.5 	(f) lorcaserin.

25.6 	EFFECTIVE DATE. This section is effective the day following final enactment.

25.7 	Sec. 4. Minnesota Statutes 2022, section 152.02, subdivision 6, is amended to read:
25.8 		Subd. 6.Schedule V; restrictions on methamphetamine precursor drugs. (a) As used 
25.9 	in this subdivision, the following terms have the meanings given:
25.10 	(1) "methamphetamine precursor drug" means any compound, mixture, or preparation 
25.11 	intended for human consumption containing ephedrine or pseudoephedrine as its sole active 
25.12 	ingredient or as one of its active ingredients; and
25.13 	(2) "over-the-counter sale" means a retail sale of a drug or product but does not include 
25.14 	the sale of a drug or product pursuant to the terms of a valid prescription.
25.15 	(b) The following items are listed in Schedule V:
25.16 	(1) any compound, mixture, or preparation containing any of the following limited 
25.17 	quantities of narcotic drugs, which shall include one or more nonnarcotic active medicinal 
25.18 	ingredients in sufficient proportion to confer upon the compound, mixture or preparation 
25.19 	valuable medicinal qualities other than those possessed by the narcotic drug alone:
25.20 	(i) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams;
25.21 	(ii) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams;
25.22 	(iii) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of 
25.23 	atropine sulfate per dosage unit;
25.24 	(iv) not more than 100 milligrams of opium per 100 milliliters or per 100 grams; or
25.25 	(v) not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of atropine 
25.26 	sulfate per dosage unit.
25.27 	(2) Stimulants. Unless specifically exempted or excluded or unless listed in another 
25.28 	schedule, any material, compound, mixture, or preparation that contains any quantity of the 
25.29 	following substance having a stimulant effect on the central nervous system, including its 
25.30 	salts, isomers, and salts of isomers: pyrovalerone.
26.1 	(3) Depressants. Unless specifically exempted or excluded or unless listed in another 
26.2 	schedule, any material, compound, mixture, or preparation that contains any quantity of the 
26.3 	following substance having a depressant effect on the central nervous system, including its 
26.4 	salts, isomers, and salts of isomers:
26.5 	(i) ezogabine;
26.6 	(ii) pregabalin;
26.7 	(iii) lacosamide.;
26.8 	(iv) cenobamate [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl]carbamate.
26.9 	(4) Any compound, mixture, or preparation containing ephedrine or pseudoephedrine 
26.10 	as its sole active ingredient or as one of its active ingredients.
26.11 	(c) No person may sell in a single over-the-counter sale more than two packages of a 
26.12 	methamphetamine precursor drug or a combination of methamphetamine precursor drugs 
26.13 	or any combination of packages exceeding a total weight of six grams, calculated as the 
26.14 	base.
26.15 	(d) Over-the-counter sales of methamphetamine precursor drugs are limited to:
26.16 	(1) packages containing not more than a total of three grams of one or more 
26.17 	methamphetamine precursor drugs, calculated in terms of ephedrine base or pseudoephedrine 
26.18 	base; or
26.19 	(2) for nonliquid products, sales in blister packs, where each blister contains not more 
26.20 	than two dosage units, or, if the use of blister packs is not technically feasible, sales in unit 
26.21 	dose packets or pouches.
26.22 	(e) A business establishment that offers for sale methamphetamine precursor drugs in 
26.23 	an over-the-counter sale shall ensure that all packages of the drugs are displayed behind a 
26.24 	checkout counter where the public is not permitted and are offered for sale only by a licensed 
26.25 	pharmacist, a registered pharmacy technician, or a pharmacy clerk. The establishment shall 
26.26 	ensure that the person making the sale requires the buyer:
26.27 	(1) to provide photographic identification showing the buyer's date of birth; and
26.28 	(2) to sign a written or electronic document detailing the date of the sale, the name of 
26.29 	the buyer, and the amount of the drug sold.
26.30 	A document described under clause (2) must be retained by the establishment for at least 
26.31 	three years and must at all reasonable times be open to the inspection of any law enforcement 
26.32 	agency.
27.1 	Nothing in this paragraph requires the buyer to obtain a prescription for the drug's 
27.2 	purchase.
27.3 	(f) No person may acquire through over-the-counter sales more than six grams of 
27.4 	methamphetamine precursor drugs, calculated as the base, within a 30-day period.
27.5 	(g) No person may sell in an over-the-counter sale a methamphetamine precursor drug 
27.6 	to a person under the age of 18 years. It is an affirmative defense to a charge under this 
27.7 	paragraph if the defendant proves by a preponderance of the evidence that the defendant 
27.8 	reasonably and in good faith relied on proof of age as described in section 340A.503, 
27.9 	subdivision 6.
27.10 	(h) A person who knowingly violates paragraph (c), (d), (e), (f), or (g) is guilty of a 
27.11 	misdemeanor and may be sentenced to imprisonment for not more than 90 days, or to 
27.12 	payment of a fine of not more than $1,000, or both.
27.13 	(i) An owner, operator, supervisor, or manager of a business establishment that offers 
27.14 	for sale methamphetamine precursor drugs whose employee or agent is convicted of or 
27.15 	charged with violating paragraph (c), (d), (e), (f), or (g) is not subject to the criminal penalties 
27.16 	for violating any of those paragraphs if the person:
27.17 	(1) did not have prior knowledge of, participate in, or direct the employee or agent to 
27.18 	commit the violation; and
27.19 	(2) documents that an employee training program was in place to provide the employee 
27.20 	or agent with information on the state and federal laws and regulations regarding 
27.21 	methamphetamine precursor drugs.
27.22 	(j) Any person employed by a business establishment that offers for sale 
27.23 	methamphetamine precursor drugs who sells such a drug to any person in a suspicious 
27.24 	transaction shall report the transaction to the owner, supervisor, or manager of the 
27.25 	establishment. The owner, supervisor, or manager may report the transaction to local law 
27.26 	enforcement. A person who reports information under this subdivision in good faith is 
27.27 	immune from civil liability relating to the report.
27.28 	(k) Paragraphs (b) to (j) do not apply to:
27.29 	(1) pediatric products labeled pursuant to federal regulation primarily intended for 
27.30 	administration to children under 12 years of age according to label instructions;
27.31 	(2) methamphetamine precursor drugs that are certified by the Board of Pharmacy as 
27.32 	being manufactured in a manner that prevents the drug from being used to manufacture 
27.33 	methamphetamine;
28.1 	(3) methamphetamine precursor drugs in gel capsule or liquid form; or
28.2 	(4) compounds, mixtures, or preparations in powder form where pseudoephedrine 
28.3 	constitutes less than one percent of its total weight and is not its sole active ingredient.
28.4 	(l) The Board of Pharmacy, in consultation with the Department of Public Safety, shall 
28.5 	certify methamphetamine precursor drugs that meet the requirements of paragraph (k), 
28.6 	clause (2), and publish an annual listing of these drugs.
28.7 	(m) Wholesale drug distributors licensed and regulated by the Board of Pharmacy 
28.8 	pursuant to sections 151.42 to 151.51 151.43 to 151.471 and registered with and regulated 
28.9 	by the United States Drug Enforcement Administration are exempt from the 
28.10 	methamphetamine precursor drug storage requirements of this section.
28.11 	(n) This section preempts all local ordinances or regulations governing the sale by a 
28.12 	business establishment of over-the-counter products containing ephedrine or 
28.13 	pseudoephedrine. All ordinances enacted prior to the effective date of this act are void.

28.14 	EFFECTIVE DATE. This section is effective the day following final enactment.